MTVA

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-102.7K ExitQ1 2026 $103k -- $1.72

Insider Trades

Name	Value	Action	Price	Last Price
Woodworth Marshall HChief Financial Officer $9.9k14.2k shares BuyJun 4, 2025 $0.70 $1.72
Dong-A St Co., Ltd10 Percent Owner $3M4.6M shares BuyMay 8, 2025 $0.71 $1.72

News

prnewswire.comMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forumprnewswire.comJun 17

globenewswire.comBioStem Technologies Announces Appointment of Three New Members to its Board of Directorsglobenewswire.comJun 9

prnewswire.comMetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potentialprnewswire.comJun 8

prnewswire.comMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conferenceprnewswire.comJun 4

prnewswire.comMetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASHprnewswire.comMay 27

Trade MTVA

About MetaVia Inc.

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

CEO: Hyung Heon Kim
IPO Date: Aug 5, 2016

Market Data

Open: $1.65
High: $1.71
Low: $1.58
Volume: 179.8K
Avg Volume: 3.7M
52W High: $19.03
52W Low: $0.966

Valuation

Market Cap: $3.5M
Enterprise Value: -$10M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$15.7M
Revenue: $0
Net Income: -$13M
Cash: $10.3M
Debt: $210K

Events

EarningsAug 6

EPS est. -0.85